• Armata Pharmaceuticals swung to third-quarter 2026 net income of $54.86 million, primarily driven by a $69.6 million convertible loan fair-value gain.
• Grant and award revenue more than doubled year over year to $3.17 million.
• Cash and cash equivalents more than doubled to $18.32 million at September 30 from December 31, 2025.
• AP-SA02 received FDA Breakthrough Therapy designation for adjunct treatment of complicated bacteremia caused by MSSA or MRSA.
• The planned AP-SA02 Phase 3 superiority study is expected to begin in the second half of 2026, pending FDA protocol concurrence.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Armata Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611121605PR_NEWS_USPR_____LA96429) on November 12, 2026, and is solely responsible for the information contained therein.